The U.K.'s National Institute for Health and Clinical Excellence decided not to endorse GlaxoSmithKline and Genmab's leukemia drug Arzerra, citing lack of evidence on the drug's effectiveness compared with standard treatment. GSK recently failed to gain NICE recommendation for cancer medicine Tyverb and platelet drug Revolade.

Full Story:

Related Summaries